Physician profile
Stephen T Ang
NPI 1346251071
$9,783.11
in general payments reported to CMS, 2019-2025
29 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,689 · 2020: $715 · 2021: $1,069 · 2022: $2,670 · 2023: $1,794 · 2024: $1,011 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,580 · Honoraria: $360 · Gift: $325 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225 · Education: $100 · Consulting Fee: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,579.52 |
| Honoraria | $360.00 |
| Gift | $325.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
| Education | $100.11 |
| Consulting Fee | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $1,947.25 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $1,524.78 | 2020-2025 | Linzess |
| Braintree Laboratories, INC. | $902.77 | 2019-2024 | Suflave, Sutab |
| Takeda Pharmaceuticals U.S.A., INC. | $858.49 | 2019-2025 | Entyvio, Eohilia |
| Abbvie INC. | $844.07 | 2019-2024 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $584.63 | 2019-2024 | Stelara |
| Allergan, INC. | $568.32 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $389.83 | 2022-2025 | Dupixent |
| Daiichi Sankyo INC. | $360.00 | 2023 | |
| Genzyme Corporation | $353.91 | 2023-2025 | |
| Celgene Corporation | $334.17 | 2021-2022 | |
| Pfizer INC. | $275.94 | 2020-2025 | |
| Shire North American Group INC | $200.00 | 2019 | |
| Ferring Pharmaceuticals INC. | $104.07 | 2019-2022 | |
| Ucb, INC. | $92.34 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $82.99 | 2019 | |
| Nestle Healthcare Nutrition INC. | $74.63 | 2021-2023 | |
| Boston Scientific Corporation | $50.00 | 2023 | |
| Becton, Dickinson and Company | $45.00 | 2024 | Bd Introsyte |
| Alfasigma USA, INC. | $33.21 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $23.59 | 2019 | |
| Blueprint Medicines Corporation | $22.44 | 2025 | Ayvakit |
| Amgen INC. | $21.67 | 2023 | Amjevita, Avsola |
| Novo Nordisk INC | $20.53 | 2025 | Wegovy |
| Pharmacosmos Therapeutics INC. | $15.54 | 2025 | Monoferric |
| Redhill Biopharma INC. | $14.78 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.54 | 2023 | Cyltezo |
| Merck Sharp & Dohme LLC | $12.39 | 2019 | |
| Olympus America INC. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.